-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
It was learned on the evening of November 30 that the FDA Drug Advisory Committee recommended the approval of Merck's emergency authorization of Molnupiravir at 13:10 with a slight advantage
Earlier (October 11), Merck announced that it had submitted an emergency authorization application (EUA) for the oral antiviral drug Molnupiravir (MK-4482) to the FDA
It is worth noting that the EUA is based on the positive interim analysis results of the Phase 3 clinical MOVe-OUT study
In the interim analysis, Molnupiravir reduced the risk of hospitalization or death by approximately 50% ; on the 29th day after randomization, 7.
Molnupiravir reduces the risk of hospitalization or death by approximately 50%
However, on November 26, Merck and Ridgeback announced updated clinical data for the new crown oral drug Molnupiravir for the treatment of mild to moderate new crowns
Reduce hospitalization or mortality by 30%
